Garde Capital Inc. Acquires 127 Shares of Amgen Inc. (AMGN)
Garde Capital Inc. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.6% during the first quarter, Holdings Channel reports. The firm owned 2,411 shares of the medical research company’s stock after buying an additional 127 shares during the period. Garde Capital Inc.’s holdings in Amgen were worth $396,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of AMGN. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. First Command Financial Services Inc. increased its position in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares during the period. Cribstone Capital Management LLC increased its position in Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock valued at $182,000 after buying an additional 25 shares during the period. Cable Hill Partners LLC increased its position in Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock valued at $161,000 after buying an additional 26 shares during the period. Finally, Howe & Rusling Inc. increased its position in Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock valued at $485,000 after buying an additional 31 shares during the period. Hedge funds and other institutional investors own 79.12% of the company’s stock.
Shares of Amgen Inc. (NASDAQ AMGN) traded down 0.09% on Tuesday, reaching $170.36. 299,624 shares of the company’s stock were exchanged. The company has a market capitalization of $124.31 billion, a P/E ratio of 15.52 and a beta of 1.35. The firm’s 50 day moving average price is $174.45 and its 200-day moving average price is $167.84. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. On average, equities analysts anticipate that Amgen Inc. will post $12.57 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.68%. Amgen’s dividend payout ratio is 41.93%.
WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/garde-capital-inc-acquires-127-shares-of-amgen-inc-amgn/1490969.html.
Several equities analysts have weighed in on the stock. UBS AG restated a “neutral” rating and set a $174.00 target price (down from $175.00) on shares of Amgen in a report on Monday, May 22nd. Mizuho set a $195.00 target price on shares of Amgen and gave the company a “buy” rating in a report on Saturday, May 6th. BMO Capital Markets restated a “buy” rating and set a $198.00 target price (down from $200.00) on shares of Amgen in a report on Monday, May 22nd. Cowen and Company restated an “outperform” rating and set a $209.00 target price on shares of Amgen in a report on Wednesday, April 19th. Finally, Morgan Stanley raised their target price on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, June 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $186.64.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.